Granted Patent B2

US 12,480,958 · App. 16/990,701 · Granted Nov 25, 2025

Inventors: Heiko Schuster (Tuebingen, DE); Meike Hutt (Tuebingen, DE); Toni Weinschenk (Tuebingen, DE); Sebastian Bunk (Tuebingen, DE); Oliver Schoor (Tuebingen, DE); Linus Backert (Tuebingen, DE); Martin Hofmann (Tuebingen, DE); Jens Fritsche (Tuebingen, DE); Felix Unverdorben (Tuebingen, DE); Gisela Schimmack (Tuebingen, DE); Florian Salopiata (Tuebingen, DE)

Assignee: Immatics Biotechnologies GmbH

G01N33/6878G01N2333/70539G01N2570/00

Abstract

Claims (66)

1 . A method for identifying the binding of a polypeptide molecule that comprises at least one defined peptide binding domain (pMHC binding polypeptide) capable of binding to a target peptide in complex with a major histocompatibility complex (MHC) molecule (peptide: MHC complex),

wherein said pMHC binding polypeptide comprises a T-cell receptor (TCR) and/or an antibody or a pMHC binding fragment thereof, and

wherein said method comprises the following steps:

a) providing a sample comprising a first off-target peptide: MHC complex and a second off-target peptide: MHC complex, wherein said sample is a cellular lysate,

b) contacting a first fraction of said sample comprising the first off-target peptide: MHC complex with said pMHC binding polypeptide, and allowing said at least one peptide binding domain of said pMHC binding polypeptide to bind to said first off-target peptide: MHC complex,

c) isolating a first off-target peptide from said first off-target peptide: MHC complex bound to said at least one peptide binding domain, and

d) identifying said first off-target peptide of said first off-target peptide: MHC complex as isolated in step c), and

e) contacting a second fraction of said sample comprising said second off-target peptide: MHC complex with an MHC pan-specific antibody or an antigen binding fragment thereof, which is capable of binding to an MHC molecule irrespective of the nature of the bound peptide,

f) isolating said second off-target peptide from said second off-target peptide: MHC complex bound to said MHC pan-specific antibody or antigen binding fragment thereof, and

g) identifying said second off-target peptide of said second off-target peptide: MHC complex as isolated in step f),

wherein said identifying in steps d) and g) comprises peptide sequencing,

wherein said first off-target peptide and said second off-target peptide comprise an identical amino acid sequence.

2 . The method according to claim 1 ,

wherein said pMHC binding polypeptide:

(i) is attached to a matrix material; or further comprises at least one attachment site binding to, or being attached to, a matrix material;

and/or

(ii) is selected from a bispecific molecule, a trispecific molecule, a tetraspecific molecule, and a multispecific molecule.

3 . The method according to claim 1 ,

wherein said pMHC binding polypeptide:

(i) is a molecule or is derived from a molecule selected from an antibody, a simultaneous multiple interaction T-cell engaging (SMITE) bispecific, a bispecific T-cell engager (BiTE), an scFv, a diabody, a dual-affinity retargeting antibody (DART), a tandem antibody (TandAb), a soluble TCR, a single chain TCR (scTCR), a mutated TCR comprising S-bridges, a truncated TCR, and a bispecific T-cell receptor (TCR)-antibody fusion molecule; and/or

(ii) comprises at least one second binding domain, wherein said second binding domain is capable of binding to a cell surface molecule selected from CD3, CD4, CD7, CD8, CD10, CD11b, CD11c, CD14, CD16, CD18, CD22, CD25, CD28, CD32a, CD32b, CD33, CD41, CD41b, CD42a, CD42b, CD44, CD45RA, CD49, CD55, CD56, CD61, CD64, CD68, CD94, CD90, CD117, CD123, CD125, CD134, CD137, CD152, CD163, CD193, CD203c, CD235a, CD278, CD279, CD287, Nkp46, NKG2D, GITR, FcεRI, TCRα/β, TCRγ/δ, and HLA-DR; and/or

(iii) is a bispecific molecule comprising a binding domain that is derived from a T cell-receptor (TCR).

4 . The method according to claim 2 , wherein the attachment site is:

a separate attachment group and that does not interfere with the binding of said pMHC binding polypeptide.

5 . The method according to claim 1 , wherein said cellular lysate is provided by generating a lysate from:

(i) peptide: MHC expressing cells; and/or

(ii) one or more tissues or cell lines, said tissue being selected from one or more primary healthy tissue samples, one or more tumor tissues from cancer patients, and infected tissue.

6 . The method according to claim 1 , wherein said identifying of step d) further comprises

(i) identifying a consensus peptide binding motif shared by said first and second off-target peptides and said target peptide for said peptide binding domain of said pMHC binding polypeptide, and/or

(ii) identifying a position-based consensus peptide binding motif shared by said first and second off-target peptides and said target peptide for said peptide binding domain of said pMHC binding polypeptide, and/or

(iii) identifying a potential cross-reactivity of said peptide binding domain of said pMHC binding polypeptide.

7 . The method according to claim 1 , wherein said peptide sequencing comprises analysis by mass spectrometry (MS), and wherein said analysis by MS comprises a quantitative assessment of peptide signal areas of MS or MS/MS.

8 . The method according to claim 6 , further comprising

(i) the step of identifying the presentation of said peptide motif or peptide motifs on cancerous and/or non-cancerous cells or tissues, and/or

(ii) adding to said sample in step a) at least

one control peptide having a known sequence and/or

one defined and/or preselected peptide: MHC complex, the peptide of which has a known sequence,

in a predetermined amount (spiking),

wherein optionally:

(a) the sequence of said one control peptide and/or the peptide of said one defined and/or preselected peptide: MHC complex is altered or mutated relative to the sequence of the target peptide in the peptide: MHC complex to which said pMHC binding polypeptide is capable of binding; and

(b) a series of mutants of the target peptide in the peptide: MHC complex to which said pMHC binding polypeptide is capable of binding is created and added to said sample in step a), each mutant having, over its entire length or over at least a subfraction thereof, the amino acid residue at one position substituted for an alternative amino acid, and

(c) each mutant has, over its entire length or over at least a subfraction thereof, the amino acid residue at one position substituted with alanine or glycine, and

(d) the anchoring positions of the target peptide in the peptide: MHC complex to which said pMHC binding polypeptide binds are not altered/mutated, and/or further comprising

(iii) a computational analysis of off-target binding of the said at least one defined peptide binding domain.

9 . The method according to claim 1 , wherein the at least one peptide binding domain comprises a detectable marker or label.

10 . The method according to claim 6 , comprising a step of further assessing the said potential cross-reactivity of said peptide binding domain of said pMHC binding polypeptide using at least one cytotoxicity assay.

11 . The method according to claim 1 , wherein:

(i) said sample does not contain the target peptide: MHC complex; or

(ii) wherein in step (b) said pMHC binding polypeptide is coupled or attached to a matrix material.

12 . The method of claim 1 , wherein said pMHC binding polypeptide comprises T-cell receptor (TCR).

13 . The method of claim 1 , wherein said pMHC binding polypeptide comprises a an antibody or a pMHC binding fragment thereof.

14 . The method of claim 1 , wherein said pMHC binding polypeptide is a bispecific molecule comprising:

(i) a first peptide binding domain (pMHC binding polypeptide) that is capable of binding to a target peptide in a complex with a major histocompatibility complex (MHC) molecule (peptide: MHC complex), wherein said first peptide binding domain is derived from a T-cell receptor (TCR); and

(ii) a second binding domain that is capable of binding to CD3.

15 . The method of claim 1 , further comprising:

h) calculating a ratio of the amounts of (i) said first off-target peptide isolated in step c) and identified in step d) and (ii) said second off-target peptide isolated in step f) and identified in step g).

16 . The method of claim 15 ,

wherein said peptide sequencing comprises analysis by mass spectrometry (MS),

wherein said analysis by MS comprises quantitative assessment of MS signal, and

wherein in step h), said ratio is calculated from the quantified MS signal of said first off-target peptide and the quantified MS signal of said second off-target peptide.

17 . The method of claim 16 , wherein said MS signal comprises a MS signal area.

18 . The method of claim 16 , wherein said MS comprises MS/MS.

19 . The method of claim 15 , wherein said ratio is a comparison of the isolation efficiency of the pMHC binding polypeptide relative to the isolation efficiency of the MHC pan-specific antibody or antigen binding fragment thereof with respect to said first and second off-target peptides.

20 . The method of claim 15 , wherein said ratio correlates with the binding affinity of said first off-target peptide:MHC complex or said second off-target peptide:MHC complex to said pMHC binding polypeptide.

21 . The method of claim 20 , wherein the binding affinity is determined by bio-layer interferometry.

22 . The method according to claim 1 , wherein said peptide sequencing comprises analysis by mass spectrometry (MS), and wherein said analysis by MS comprises a quantitative assessment of peptide signal intensities of MS or MS/MS.

Assignments (1)

Priority Claims (1)

Continuity (2)

References Cited (50)